rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
2010-12-29
|
pubmed:abstractText |
Abraxane (nanoparticle albumin-bound paclitaxel) is an anticancer drug approved by the Food and Drug Administration. However, the mechanism of action of Abraxane is complex, and no established biomarker is available to accurately monitor its treatment outcomes. The aim of this study was to investigate whether the integrin-specific PET tracer 18F-FPPRGD2 (investigational new drug 104150) can be used to monitor early response of tumors to Abraxane therapy.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1535-5667
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
52
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
140-6
|
pubmed:meshHeading |
pubmed-meshheading:21149494-Albumins,
pubmed-meshheading:21149494-Animals,
pubmed-meshheading:21149494-Antineoplastic Agents,
pubmed-meshheading:21149494-Cell Line, Tumor,
pubmed-meshheading:21149494-Female,
pubmed-meshheading:21149494-Fluorine Radioisotopes,
pubmed-meshheading:21149494-Fluorodeoxyglucose F18,
pubmed-meshheading:21149494-Humans,
pubmed-meshheading:21149494-Integrin alphaVbeta3,
pubmed-meshheading:21149494-Mammary Neoplasms, Experimental,
pubmed-meshheading:21149494-Mice,
pubmed-meshheading:21149494-Oligopeptides,
pubmed-meshheading:21149494-Paclitaxel,
pubmed-meshheading:21149494-Positron-Emission Tomography,
pubmed-meshheading:21149494-Radiopharmaceuticals,
pubmed-meshheading:21149494-Xenograft Model Antitumor Assays
|
pubmed:year |
2011
|
pubmed:articleTitle |
18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy.
|
pubmed:affiliation |
Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892-2281, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Intramural
|